PMC4607072_01
Schematic representation of time line of disease progression and treatments for Case 1.. Note: TAC, docetaxel + doxorubicin + cyclophosphamide.
cmo-9-2015-081f1.jpg
PMC4607072_01_cmo-9-2015-081f1.jpg
f1-cmo-9-2015-081
A complete time line of the patient's treatment history is summarized in Figure 1.
PMC4607072_02
PMC4607072_03
PMC4607072_04
PMC4607072_05
Schematic representation of time line of disease progression and treatments for Case 2.. Note: DD AC T, dose-dense doxorubicin + cyclophosphamide, followed by paclitaxel.
cmo-9-2015-081f2.jpg
PMC4607072_06_cmo-9-2015-081f2.jpg
f2-cmo-9-2015-081
As shown in Figure 2, she experienced a partial response with eribulin that was sustained until February 2011, when she again developed progressive disease in bone and liver.
PMC4607072_06
Schematic representation of time line of disease progression and treatments for Case 2.. Note: DD AC T, dose-dense doxorubicin + cyclophosphamide, followed by paclitaxel.
cmo-9-2015-081f2.jpg
PMC4607072_06_cmo-9-2015-081f2.jpg
f2-cmo-9-2015-081
As shown in Figure 2, she experienced a partial response with eribulin that was sustained until February 2011, when she again developed progressive disease in bone and liver.